Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Synthetic molecules as antibody replacements.

Thomas Kodadek1, M Muralidhar Reddy, Hernando J Olivos

  • 1Center for Biomedical Inventions, Departments of Internal Medicine and Molecular Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-8573, USA. Thomas.Kodadek@utsouthwestern.edu

Accounts of Chemical Research
|September 24, 2004
PubMed
Summary

Researchers are developing synthetic molecules to replace antibodies, aiming for similar high affinity and specificity. This review explores methods for creating robust synthetic protein binders with antibody-like characteristics for biological research and therapeutics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A high throughput assay to identify modulators of Death Receptor 3 (DR3).

SLAS discovery : advancing life sciences R & D·2026
Same author

Assessing the suitability of deubiquitylases as substrates for targeted protein degradation.

Cell chemical biology·2026
Same author

A novel subset of hepatocytes is simultaneously gluconeogenic and <i>de novo</i> lipogenic in the fed state and is naturally insulin resistant.

bioRxiv : the preprint server for biology·2026
Same author

Macrocyclic Peptides Containing an Imidazopyridinium (IP<sup>+</sup>) Unit Display Enhanced Passive Cell Permeability.

Journal of the American Chemical Society·2026
Same author

Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models.

bioRxiv : the preprint server for biology·2026
Same author

Overcoming limitations of targeted protein degraders: developments toward reversible, self-assembling degraders.

Future medicinal chemistry·2026

Area of Science:

  • Biochemistry and Molecular Biology
  • Protein Engineering
  • Biotechnology

Background:

  • Antibodies are indispensable protein-binding agents in biological research and therapeutics.
  • Current antibodies possess practical limitations hindering their broader application.
  • There is a need for simpler, more robust synthetic alternatives to antibodies.

Purpose of the Study:

  • To review strategies for overcoming limitations of synthetic protein-binding agents.
  • To explore the development of high-throughput methods for isolating synthetic ligands.
  • To achieve antibody-like binding affinity and specificity in synthetic molecules.

Main Methods:

  • Review of existing literature on synthetic protein-binding agent development.
  • Analysis of methodologies for enhancing affinity and specificity of synthetic ligands.

Related Experiment Videos

  • Exploration of high-throughput screening and selection techniques.

    • Main Results:

    • Synthetic protein-binding agents often lack the high affinity and specificity of antibodies.
    • Progress has been made in designing synthetic molecules with improved binding characteristics.
    • Facile, high-throughput methodologies are crucial for isolating effective synthetic ligands.

    Conclusions:

    • Developing synthetic molecules with antibody-like properties is a significant challenge.
    • Continued research into novel methodologies is essential for advancing synthetic binders.
    • Successful synthetic ligands will offer robust alternatives for research and therapeutic applications.